prodrugs

Results: 1086



#Item
341DRUG PRIOR AUTHORIZATION COMMITTEE December 18, 2014 TENTATIVE AGENDA 10:[removed]:05

DRUG PRIOR AUTHORIZATION COMMITTEE December 18, 2014 TENTATIVE AGENDA 10:[removed]:05

Add to Reading List

Source URL: dss.mo.gov

Language: English - Date: 2014-12-15 14:38:11
342The Tangled Web of Addiction and Crime What We’ve Accomplished • Raised the Public’s awareness of the dangers of Rx Drugs and educated the medical community to be more diligent in their prescribing practices.

The Tangled Web of Addiction and Crime What We’ve Accomplished • Raised the Public’s awareness of the dangers of Rx Drugs and educated the medical community to be more diligent in their prescribing practices.

Add to Reading List

Source URL: www.state.tn.us

Language: English - Date: 2014-12-11 08:39:28
343LOPID  (Gemfibrozil Tablets, USP) DESCRIPTION LOPID® (gemfibrozil tablets, USP) is a lipid regulating agent. It is available as tablets for

LOPID (Gemfibrozil Tablets, USP) DESCRIPTION LOPID® (gemfibrozil tablets, USP) is a lipid regulating agent. It is available as tablets for

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2014-11-06 11:32:51
344UKPAR Ramipril 1.25 mg, 2.5 mg, 5 mg and 10 mg Capsules  PL[removed]Ramipril 1.25 mg Capsules Ramipril 2.5 mg Capsules

UKPAR Ramipril 1.25 mg, 2.5 mg, 5 mg and 10 mg Capsules PL[removed]Ramipril 1.25 mg Capsules Ramipril 2.5 mg Capsules

Add to Reading List

Source URL: www.mhra.gov.uk

Language: English - Date: 2015-01-08 11:26:51
345A Law Enforcement Perspective   Zohydro  First hydrocodone-only opioid narcotic that is reportedly five to ten times more potent than traditional hydrocodone products, and has no abuse-deterrent properties.

A Law Enforcement Perspective  Zohydro  First hydrocodone-only opioid narcotic that is reportedly five to ten times more potent than traditional hydrocodone products, and has no abuse-deterrent properties.

Add to Reading List

Source URL: www.in.gov

Language: English - Date: 2014-12-17 14:23:23
346July 26 Webinar, Center for Medicaid and CHIP Services, Draft Methodology for Estimating National Average Retail Prices (NARP) for Medicaid Covered Outpatient Drugs

July 26 Webinar, Center for Medicaid and CHIP Services, Draft Methodology for Estimating National Average Retail Prices (NARP) for Medicaid Covered Outpatient Drugs

Add to Reading List

Source URL: medicaid.gov

Language: English - Date: 2014-12-04 14:16:40
347July 26 Webinar, Center for Medicaid and CHIP Services, Draft Methodology for Estimating National Average Retail Prices (NARP) for Medicaid Covered Outpatient Drugs

July 26 Webinar, Center for Medicaid and CHIP Services, Draft Methodology for Estimating National Average Retail Prices (NARP) for Medicaid Covered Outpatient Drugs

Add to Reading List

Source URL: www.medicaid.gov

Language: English - Date: 2014-12-04 14:16:40
348NOTICE: USP Prednisone Tablets RS Lot R001B0 and Performance Verification Test Calculation Tool The certificate for USP Catalog No[removed], Prednisone Tablets RS, Lot R001B0 issued 3 September 2014 has been revised. The

NOTICE: USP Prednisone Tablets RS Lot R001B0 and Performance Verification Test Calculation Tool The certificate for USP Catalog No[removed], Prednisone Tablets RS, Lot R001B0 issued 3 September 2014 has been revised. The

Add to Reading List

Source URL: www.usp.org

Language: English - Date: 2014-10-30 13:57:59
349Arkansas Department of Health Proposed Rules Pertaining to the List of Controlled Substances for the State of Arkansas Public Comments Received A public hearing was conducted September 2, 2014, at 10:00 a.m. in Room #250

Arkansas Department of Health Proposed Rules Pertaining to the List of Controlled Substances for the State of Arkansas Public Comments Received A public hearing was conducted September 2, 2014, at 10:00 a.m. in Room #250

Add to Reading List

Source URL: www.healthy.arkansas.gov

Language: English - Date: 2014-12-16 15:11:23
350HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XELODA safely and effectively. See full prescribing information for XELODA.  ------------------------------ CO

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use XELODA safely and effectively. See full prescribing information for XELODA. ------------------------------ CO

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2014-10-17 10:50:06